, Tracking Stock Market Picks
Enter Symbol:
Evogene Ltd. (EVGN) [hlAlert]

down 55.36 %

Evogene Ltd. (EVGN) rated Outperform with price target $26 by Oppenheimer

Posted on: Monday,  Dec 16, 2013  8:25 AM ET by Oppenheimer

Oppenheimer rated Outperform Evogene Ltd. (NYSE: EVGN) on 12/16/2013, when the stock price was $18.75. Since
then, Evogene Ltd. has lost 55.36% as of 08/27/2015's recent price of $8.37.
If you would have followed this Oppenheimer's recommendation on EVGN, you would have lost 55.36% of your investment in 619 days.

Evogene Ltd., a biotech company, engages in the research and development of improved plants for the agriculture and biofuel industries. It discovers and develops genes for the enhancement of plant traits comprising yield under normal and various environmental stress conditions, such as drought and fertilizer utilization; and develops high oil yielding plant varieties for biofuels production. The company holds pending IP rights to approximately 1500 novel genes validated in plants relating to principal plant traits. It has an investment and collaboration agreement with Monsanto Company for gene development and granted exclusivity for the use and marketing of genes developed; and an agreement with Bayer CropScience AG that grants Bayer an exclusive license for the use and commercialization of rice-based genes. The company also has collaboration agreements with Syngenta to identify genes having a potential to improve nematode resistance; and with SLC Agricola SA for the development of castor bean seeds as a feedstock for biofuels. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.

OppenheimerFunds, Inc. has been helping investors achieve their financial goals since 1960. We are one of the nation's largest and most respected asset management companies. At OppenheimerFunds, we believe that in order for you to reach your financial goals, your investments must perform. That is why investment excellence—over the long term and across the range of our products—is our highest priority. OppenheimerFunds and its controlled affiliates offer a broad range of products and services to individuals, corporations and institutions, including mutual funds, separately managed accounts, investment management for institutions, hedge fund products, qualified retirement plans and subadvisory investment-management services.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
12/16/2013 8:25 AM Buy
18.75 26.00
as of 8/27/2015
1 Week down  -8.72 %
1 Month down  -8.52 %
3 Months down  -16.30 %
1 YTD down  -57.40 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy